SEC Form 4 · accession 0000880771-16-000179
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Anthony Low
Officer — VP, Finance & Controller
Period of report
Aug 12, 2016
Accepted (ET)
Aug 16, 2016 · 5:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 12, 2016 | M | 1,250 | $0.00 | A | 10,908 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3,F4 | — | Aug 12, 2016 | A | 10,000 | A | — | — | Common Stock | 10,000 | 20,000 | D |
| Restricted Stock UnitF5,F3,F6 | — | Aug 12, 2016 | M | 1,250 | D | — | — | Common Stock | 1,250 | 18,750 | D |
Explanation of responses
- F1Includes 9,658 shares purchased under the Issuer's Employee Stock Purchase Plan from February 28, 2014 through May 31, 2016.
- F2Granted under the Issuer's 2015 Equity Incentive Plan.
- F3Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F4Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
- F5Granted under the Issuer's 2005 Equity Incentive Plan.
- F6Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.